{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:34:08Z","timestamp":1787668448607,"version":"build-2736575974"},"reference-count":141,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["T32AG071745"],"award-info":[{"award-number":["T32AG071745"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The development of anti-amyloid-beta (A\u03b2) immunotherapies as the first disease modifying therapy for Alzheimer\u2019s Disease (AD) is a breakthrough of basic research and translational science.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Main text<\/jats:title>\n            <jats:p>Genetically modified mouse models developed to study AD neuropathology and physiology were used for the discovery of A\u03b2 immunotherapies and helped ultimately propel therapies to FDA approval. Nonetheless, the combination of modest efficacy and significant rates of an adverse side effect (amyloid related imaging abnormalities, ARIA), has prompted reverse translational research in these same mouse models to better understand the mechanism of the therapies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This review considers the use of these mouse models in understanding the mechanisms of A\u03b2 clearance, cerebral amyloid angiopathy (CAA), blood brain barrier breakdown, neuroinflammation, and neuronal dysfunction in response to A\u03b2 immunotherapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13024-025-00836-x","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T14:52:01Z","timestamp":1747147921000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Mouse models of Anti-A\u03b2 immunotherapies"],"prefix":"10.1186","volume":"20","author":[{"given":"Philip","family":"Pikus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Scott","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6276-248X","authenticated-orcid":false,"given":"G. William","family":"Rebeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"issue":"1","key":"836_CR1","first-page":"5","volume":"38","author":"J Cummings","year":"2024","unstructured":"Cummings J, Osse AML, Cammann D, Powell J, Chen J. Anti-Amyloid monoclonal antibodies for the treatment of Alzheimer\u2019s disease. BioDrugs Clin Immunother Biopharm Gene Ther. 2024;38(1):5\u201322.","journal-title":"BioDrugs Clin Immunother Biopharm Gene Ther"},{"issue":"10","key":"836_CR2","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/0165-6147(91)90609-V","volume":"12","author":"J Hardy","year":"1991","unstructured":"Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer\u2019s disease. Trends Pharmacol Sci. 1991;12(10):383\u20138.","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"836_CR3","first-page":"32","volume":"11","author":"A Rashad","year":"2022","unstructured":"Rashad A, Rasool A, Shaheryar M, Sarfraz A, Sarfraz Z, Robles-Velasco K, et al. Donanemab for Alzheimer\u2019s disease: A systematic review of clinical trials. Healthc Basel Switz. 2022;11(1):32.","journal-title":"Healthc Basel Switz"},{"issue":"4","key":"836_CR4","doi-asserted-by":"publisher","first-page":"562","DOI":"10.2214\/AJR.22.28461","volume":"220","author":"M Roytman","year":"2023","unstructured":"Roytman M, Mashriqi F, Al-Tawil K, Schulz PE, Zaharchuk G, Benzinger TLS, et al. Amyloid-Related imaging abnormalities: an update. AJR Am J Roentgenol. 2023;220(4):562\u201374.","journal-title":"AJR Am J Roentgenol"},{"key":"836_CR5","doi-asserted-by":"publisher","first-page":"1326784","DOI":"10.3389\/fnins.2024.1326784","volume":"18","author":"SJ Doran","year":"2024","unstructured":"Doran SJ, Sawyer RP. Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications. Front Neurosci. 2024;18:1326784.","journal-title":"Front Neurosci"},{"issue":"2","key":"836_CR6","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/ana.10810","volume":"55","author":"JA Eng","year":"2004","unstructured":"Eng JA, Frosch MP, Choi K, Rebeck GW, Greenberg SM. Clinical manifestations of cerebral amyloid angiopathy-related inflammation. Ann Neurol. 2004;55(2):250\u20136.","journal-title":"Ann Neurol"},{"issue":"2","key":"836_CR7","doi-asserted-by":"publisher","first-page":"E13","DOI":"10.3174\/ajnr.A7759","volume":"44","author":"M Zedde","year":"2023","unstructured":"Zedde M, Pascarella R, Piazza F. CAA-ri and ARIA: two faces of the same coin?? AJNR Am J Neuroradiol. 2023;44(2):E13\u20134.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"6514","key":"836_CR8","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/373523a0","volume":"373","author":"D Games","year":"1995","unstructured":"Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, et al. Alzheimer-type neuropathology in Transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 1995;373(6514):523\u20137.","journal-title":"Nature"},{"issue":"7","key":"836_CR9","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1097\/01.jnen.0000171644.00180.fc","volume":"64","author":"SB Domnitz","year":"2005","unstructured":"Domnitz SB, Robbins EM, Hoang AW, Garcia-Alloza M, Hyman BT, Rebeck GW, et al. Progression of cerebral amyloid angiopathy in Transgenic mouse models of alzheimer disease. J Neuropathol Exp Neurol. 2005;64(7):588\u201394.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"6740","key":"836_CR10","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/22124","volume":"400","author":"D Schenk","year":"1999","unstructured":"Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400(6740):173\u20137.","journal-title":"Nature"},{"issue":"40","key":"836_CR11","doi-asserted-by":"publisher","first-page":"10129","DOI":"10.1523\/JNEUROSCI.1202-06.2006","volume":"26","author":"H Oakley","year":"2006","unstructured":"Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in Transgenic mice with five Familial Alzheimer\u2019s disease mutations: potential factors in amyloid plaque formation. J Neurosci Off J Soc Neurosci. 2006;26(40):10129\u201340.","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"836_CR12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40478-015-0250-y","volume":"3","author":"F Liao","year":"2015","unstructured":"Liao F, Zhang TJ, Jiang H, Lefton KB, Robinson GO, Vassar R, et al. Murine versus human Apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP Transgenic mouse models. Acta Neuropathol Commun. 2015;3:70.","journal-title":"Acta Neuropathol Commun"},{"issue":"10","key":"836_CR13","doi-asserted-by":"publisher","first-page":"5404","DOI":"10.3390\/ijms23105404","volume":"23","author":"R Sanchez-Varo","year":"2022","unstructured":"Sanchez-Varo R, Mejias-Ortega M, Fernandez-Valenzuela JJ, Nu\u00f1ez-Diaz C, Caceres-Palomo L, Vegas-Gomez L, et al. Transgenic mouse models of Alzheimer\u2019s disease: an integrative analysis. Int J Mol Sci. 2022;23(10):5404.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"836_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1006\/nbdi.1996.0023","volume":"3","author":"PT Xu","year":"1996","unstructured":"Xu PT, Schmechel D, Rothrock-Christian T, Burkhart DS, Qiu HL, Popko B, et al. Human Apolipoprotein E2, E3, and E4 isoform-specific Transgenic mice: human-like pattern of glial and neuronal immunoreactivity in central nervous system not observed in wild-type mice. Neurobiol Dis. 1996;3(3):229\u201345.","journal-title":"Neurobiol Dis"},{"issue":"50","key":"836_CR15","doi-asserted-by":"publisher","first-page":"41774","DOI":"10.1074\/jbc.M112.407957","volume":"287","author":"KL Youmans","year":"2012","unstructured":"Youmans KL, Tai LM, Nwabuisi-Heath E, Jungbauer L, Kanekiyo T, Gan M, et al. APOE4-specific changes in A\u03b2 accumulation in a new Transgenic mouse model of alzheimer disease. J Biol Chem. 2012;287(50):41774\u201386.","journal-title":"J Biol Chem"},{"issue":"5284","key":"836_CR16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1126\/science.274.5284.99","volume":"274","author":"K Hsiao","year":"1996","unstructured":"Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in Transgenic mice. Science. 1996;274(5284):99\u2013102.","journal-title":"Science"},{"key":"836_CR17","doi-asserted-by":"publisher","first-page":"912995","DOI":"10.3389\/fnmol.2022.912995","volume":"15","author":"M Yokoyama","year":"2022","unstructured":"Yokoyama M, Kobayashi H, Tatsumi L, Tomita T. Mouse models of Alzheimer\u2019s disease. Front Mol Neurosci. 2022;15:912995.","journal-title":"Front Mol Neurosci"},{"issue":"Pt 9","key":"836_CR18","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1093\/brain\/awm156","volume":"130","author":"HK Shin","year":"2007","unstructured":"Shin HK, Jones PB, Garcia-Alloza M, Borrelli L, Greenberg SM, Bacskai BJ, et al. Age-dependent cerebrovascular dysfunction in a Transgenic mouse model of cerebral amyloid angiopathy. Brain J Neurol. 2007;130(Pt 9):2310\u20139.","journal-title":"Brain J Neurol"},{"issue":"3","key":"836_CR19","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S0896-6273(03)00434-3","volume":"39","author":"S Oddo","year":"2003","unstructured":"Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer\u2019s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39(3):409\u201321.","journal-title":"Neuron"},{"key":"836_CR20","doi-asserted-by":"publisher","first-page":"593927","DOI":"10.3389\/fnagi.2021.593927","volume":"13","author":"LA Gonz\u00e1lez-Molina","year":"2021","unstructured":"Gonz\u00e1lez-Molina LA, Villar-Vesga J, Henao-Restrepo J, Villegas A, Lopera F, Cardona-G\u00f3mez GP, et al. Extracellular vesicles from 3xTg-AD mouse and Alzheimer\u2019s disease patient astrocytes impair neuroglial and vascular components. Front Aging Neurosci. 2021;13:593927.","journal-title":"Front Aging Neurosci"},{"key":"836_CR21","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.neurobiolaging.2021.04.019","volume":"105","author":"DD Quintana","year":"2021","unstructured":"Quintana DD, Anantula Y, Garcia JA, Engler-Chiurazzi EB, Sarkar SN, Corbin DR, et al. Microvascular degeneration occurs before plaque onset and progresses with age in 3xTg AD mice. Neurobiol Aging. 2021;105:115\u201328.","journal-title":"Neurobiol Aging"},{"issue":"9","key":"836_CR22","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/sj.embor.7400784","volume":"7","author":"R Radde","year":"2006","unstructured":"Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, et al. Abeta42-driven cerebral amyloidosis in Transgenic mice reveals early and robust pathology. EMBO Rep. 2006;7(9):940\u20136.","journal-title":"EMBO Rep"},{"issue":"194","key":"836_CR23","doi-asserted-by":"publisher","first-page":"194re2","DOI":"10.1126\/scitranslmed.3006446","volume":"5","author":"LF Maia","year":"2013","unstructured":"Maia LF, Kaeser SA, Reichwald J, Hruscha M, Martus P, Staufenbiel M, et al. Changes in amyloid-\u03b2 and Tau in the cerebrospinal fluid of Transgenic mice overexpressing amyloid precursor protein. Sci Transl Med. 2013;5(194):194re2.","journal-title":"Sci Transl Med"},{"issue":"9","key":"836_CR24","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.15252\/embr.201744067","volume":"18","author":"L Ye","year":"2017","unstructured":"Ye L, Rasmussen J, Kaeser SA, Marzesco AM, Oberm\u00fcller U, Mahler J, et al. A\u03b2 seeding potency peaks in the early stages of cerebral \u03b2-amyloidosis. EMBO Rep. 2017;18(9):1536\u201344.","journal-title":"EMBO Rep"},{"issue":"24","key":"836_CR25","doi-asserted-by":"publisher","first-page":"13287","DOI":"10.1073\/pnas.94.24.13287","volume":"94","author":"C Sturchler-Pierrat","year":"1997","unstructured":"Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, et al. Two amyloid precursor protein Transgenic mouse models with alzheimer disease-like pathology. Proc Natl Acad Sci U S A. 1997;94(24):13287\u201392.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"836_CR26","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1016\/j.neurobiolaging.2015.03.011","volume":"36","author":"J Mahler","year":"2015","unstructured":"Mahler J, Morales-Corraliza J, Stolz J, Skodras A, Radde R, Duma CC, et al. Endogenous murine A\u03b2 increases amyloid deposition in APP23 but not in APPPS1 Transgenic mice. Neurobiol Aging. 2015;36(7):2241\u20137.","journal-title":"Neurobiol Aging"},{"issue":"5","key":"836_CR27","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1523\/JNEUROSCI.21-05-01619.2001","volume":"21","author":"DT Winkler","year":"2001","unstructured":"Winkler DT, Bondolfi L, Herzig MC, Jann L, Calhoun ME, Wiederhold KH, et al. Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy. J Neurosci Off J Soc Neurosci. 2001;21(5):1619\u201327.","journal-title":"J Neurosci Off J Soc Neurosci"},{"issue":"11","key":"836_CR28","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1523\/JNEUROSCI.20-11-04050.2000","volume":"20","author":"L Mucke","year":"2000","unstructured":"Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, et al. High-level neuronal expression of Abeta 1\u201342 in wild-type human amyloid protein precursor Transgenic mice: synaptotoxicity without plaque formation. J Neurosci Off J Soc Neurosci. 2000;20(11):4050\u20138.","journal-title":"J Neurosci Off J Soc Neurosci"},{"issue":"6286","key":"836_CR29","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1126\/science.aad8373","volume":"352","author":"S Hong","year":"2016","unstructured":"Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, et al. Complement and microglia mediate early synapse loss in alzheimer mouse models. Science. 2016;352(6286):712\u20136.","journal-title":"Science"},{"issue":"4","key":"836_CR30","doi-asserted-by":"publisher","first-page":"e59586","DOI":"10.1371\/journal.pone.0059586","volume":"8","author":"AL Wright","year":"2013","unstructured":"Wright AL, Zinn R, Hohensinn B, Konen LM, Beynon SB, Tan RP, et al. Neuroinflammation and neuronal loss precede A\u03b2 plaque deposition in the hAPP-J20 mouse model of Alzheimer\u2019s disease. PLoS ONE. 2013;8(4):e59586.","journal-title":"PLoS ONE"},{"issue":"52","key":"836_CR31","doi-asserted-by":"publisher","first-page":"14156","DOI":"10.1523\/JNEUROSCI.4147-08.2008","volume":"28","author":"J Koenigsknecht-Talboo","year":"2008","unstructured":"Koenigsknecht-Talboo J, Meyer-Luehmann M, Parsadanian M, Garcia-Alloza M, Finn MB, Hyman BT, et al. Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice. J Neurosci Off J Soc Neurosci. 2008;28(52):14156\u201364.","journal-title":"J Neurosci Off J Soc Neurosci"},{"issue":"4","key":"836_CR32","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1073\/pnas.0436286100","volume":"100","author":"F Bard","year":"2003","unstructured":"Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, et al. Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer\u2019s disease-like neuropathology. Proc Natl Acad Sci U S A. 2003;100(4):2023\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"836_CR33","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1093\/carcin\/13.6.917","volume":"13","author":"JD Groopman","year":"1992","unstructured":"Groopman JD, Skipper PL, Donahue PR, Trudel LJ, Wildschutte M, Kadlubar FF, et al. Monoclonal antibodies and rabbit antisera recognizing 4-aminobiphenyl\u2013DNA adducts and application to immunoaffinity chromatography. Carcinogenesis. 1992;13(6):917\u201322.","journal-title":"Carcinogenesis"},{"issue":"5","key":"836_CR34","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.neuron.2012.10.029","volume":"76","author":"RB Demattos","year":"2012","unstructured":"Demattos RB, Lu J, Tang Y, Racke MM, Delong CA, Tzaferis JA, et al. A plaque-specific antibody clears existing \u03b2-amyloid plaques in Alzheimer\u2019s disease mice. Neuron. 2012;76(5):908\u201320.","journal-title":"Neuron"},{"issue":"4","key":"836_CR35","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1073\/pnas.94.4.1550","volume":"94","author":"K Johnson-Wood","year":"1997","unstructured":"Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, et al. Amyloid precursor protein processing and A beta42 deposition in a Transgenic mouse model of alzheimer disease. Proc Natl Acad Sci U S A. 1997;94(4):1550\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"836_CR36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1742-2094-7-57","volume":"7","author":"SS Minami","year":"2010","unstructured":"Minami SS, Sidahmed E, Aid S, Shimoji M, Niikura T, Mocchetti I, et al. Therapeutic versus neuroinflammatory effects of passive immunization is dependent on A\u03b2\/amyloid burden in a Transgenic mouse model of Alzheimer\u2019s disease. J Neuroinflammation. 2010;7:57.","journal-title":"J Neuroinflammation"},{"issue":"6","key":"836_CR37","doi-asserted-by":"publisher","first-page":"e0180076","DOI":"10.1371\/journal.pone.0180076","volume":"12","author":"HY Xing","year":"2017","unstructured":"Xing HY, Li B, Peng D, Wang CY, Wang GY, Li P, et al. A novel monoclonal antibody against the N-terminus of A\u03b21\u201342 reduces plaques and improves cognition in a mouse model of Alzheimer\u2019s disease. PLoS ONE. 2017;12(6):e0180076.","journal-title":"PLoS ONE"},{"issue":"4","key":"836_CR38","doi-asserted-by":"publisher","first-page":"384","DOI":"10.2174\/1567205012666150325183708","volume":"12","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Zou J, Yang J, Yao Z. 4A\u03b21-15-Derived monoclonal antibody reduces more A\u03b2 burdens and neuroinflammation than homologous vaccine in APP\/PS1 mice. Curr Alzheimer Res. 2015;12(4):384\u201397.","journal-title":"Curr Alzheimer Res"},{"issue":"5597","key":"836_CR39","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1126\/science.1078259","volume":"298","author":"M Pfeifer","year":"2002","unstructured":"Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, et al. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science. 2002;298(5597):1379.","journal-title":"Science"},{"issue":"7618","key":"836_CR40","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussi\u00e8re T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature. 2016;537(7618):50\u20136.","journal-title":"Nature"},{"issue":"2","key":"836_CR41","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2022;9(2):197\u2013210.","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"836_CR42","doi-asserted-by":"publisher","first-page":"6412","DOI":"10.1038\/s41598-018-24501-0","volume":"8","author":"JW Arndt","year":"2018","unstructured":"Arndt JW, Qian F, Smith BA, Quan C, Kilambi KP, Bush MW, et al. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-\u03b2. Sci Rep. 2018;8(1):6412.","journal-title":"Sci Rep"},{"issue":"27","key":"836_CR43","doi-asserted-by":"publisher","first-page":"6144","DOI":"10.1523\/JNEUROSCI.1090-04.2004","volume":"24","author":"DM Wilcock","year":"2004","unstructured":"Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, Alamed J, et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a Transgenic mouse model of amyloid deposition. J Neurosci Off J Soc Neurosci. 2004;24(27):6144\u201351.","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"836_CR44","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1742-2094-3-11","volume":"3","author":"NC Carty","year":"2006","unstructured":"Carty NC, Wilcock DM, Rosenthal A, Grimm J, Pons J, Ronan V, et al. Intracranial administration of deglycosylated C-terminal-specific anti-Abeta antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing Transgenic mice. J Neuroinflammation. 2006;3:11.","journal-title":"J Neuroinflammation"},{"issue":"4","key":"836_CR45","doi-asserted-by":"publisher","first-page":"414","DOI":"10.14283\/jpad.2021.56","volume":"8","author":"SL Lowe","year":"2021","unstructured":"Lowe SL, Duggan Evans C, Shcherbinin S, Cheng YJ, Willis BA, Gueorguieva I, et al. Donanemab (LY3002813) phase 1b study in Alzheimer\u2019s disease: rapid and sustained reduction of brain amyloid measured by Florbetapir F18 imaging. J Prev Alzheimers Dis. 2021;8(4):414\u201324.","journal-title":"J Prev Alzheimers Dis"},{"issue":"2","key":"836_CR46","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ajpath.2013.05.005","volume":"183","author":"JL Frost","year":"2013","unstructured":"Frost JL, Le KX, Cynis H, Ekpo E, Kleinschmidt M, Palmour RM, et al. Pyroglutamate-3 amyloid-\u03b2 deposition in the brains of humans, non-human primates, canines, and alzheimer disease-like Transgenic mouse models. Am J Pathol. 2013;183(2):369\u201381.","journal-title":"Am J Pathol"},{"key":"836_CR47","doi-asserted-by":"publisher","first-page":"103949","DOI":"10.1016\/j.mcn.2024.103949","volume":"130","author":"M Johannesson","year":"2024","unstructured":"Johannesson M, S\u00f6derberg L, Zachrisson O, Fritz N, Kylefjord H, Gkanatsiou E, et al. Lecanemab demonstrates highly selective binding to A\u03b2 protofibrils isolated from Alzheimer\u2019s disease brains. Mol Cell Neurosci. 2024;130:103949.","journal-title":"Mol Cell Neurosci"},{"issue":"1","key":"836_CR48","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/j.1471-4159.2007.04759.x","volume":"103","author":"H Englund","year":"2007","unstructured":"Englund H, Sehlin D, Johansson AS, Nilsson LNG, Gellerfors P, Paulie S, et al. Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. J Neurochem. 2007;103(1):334\u201345.","journal-title":"J Neurochem"},{"issue":"16","key":"836_CR49","doi-asserted-by":"publisher","first-page":"8947","DOI":"10.3390\/ijms22168947","volume":"22","author":"P Gogesch","year":"2021","unstructured":"Gogesch P, Dudek S, van Zandbergen G, Waibler Z, Anzaghe M. The role of Fc receptors on the effectiveness of therapeutic monoclonal antibodies. Int J Mol Sci. 2021;22(16):8947.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"836_CR50","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s12017-009-8099-5","volume":"12","author":"E Okun","year":"2010","unstructured":"Okun E, Mattson MP, Arumugam TV. Involvement of Fc receptors in disorders of the central nervous system. Neuromolecular Med. 2010;12(2):164\u201378.","journal-title":"Neuromolecular Med"},{"issue":"8","key":"836_CR51","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/78682","volume":"6","author":"F Bard","year":"2000","unstructured":"Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of alzheimer disease. Nat Med. 2000;6(8):916\u20139.","journal-title":"Nat Med"},{"key":"836_CR52","doi-asserted-by":"publisher","first-page":"980250","DOI":"10.1155\/2012\/980250","volume":"2012","author":"ZA Ahmad","year":"2012","unstructured":"Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen NBM, Hamid M. ScFv antibody: principles and clinical application. Clin Dev Immunol. 2012;2012:980250.","journal-title":"Clin Dev Immunol"},{"issue":"4","key":"836_CR53","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.3233\/JAD-190484","volume":"70","author":"G Esquerda-Canals","year":"2019","unstructured":"Esquerda-Canals G, Roda AR, Mart\u00ed-Cl\u00faa J, Montoliu-Gaya L, Rivera-Hern\u00e1ndez G, Villegas S. Treatment with scFv-h3D6 prevented neuronal loss and improved Spatial memory in young 3xTg-AD mice by reducing the intracellular Amyloid-\u03b2 burden. J Alzheimers Dis JAD. 2019;70(4):1069\u201391.","journal-title":"J Alzheimers Dis JAD"},{"issue":"1","key":"836_CR54","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13195-023-01236-3","volume":"15","author":"T Gustavsson","year":"2023","unstructured":"Gustavsson T, Metzendorf NG, Wik E, Roshanbin S, Julku U, Chourlia A, et al. Long-term effects of immunotherapy with a brain penetrating A\u03b2 antibody in a mouse model of Alzheimer\u2019s disease. Alzheimers Res Ther. 2023;15(1):90.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"836_CR55","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13195-018-0377-8","volume":"10","author":"S Syv\u00e4nen","year":"2018","unstructured":"Syv\u00e4nen S, Hultqvist G, Gustavsson T, Gumucio A, Laudon H, S\u00f6derberg L, et al. Efficient clearance of A\u03b2 protofibrils in A\u03b2PP-transgenic mice treated with a brain-penetrating bifunctional antibody. Alzheimers Res Ther. 2018;10(1):49.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"836_CR56","doi-asserted-by":"publisher","first-page":"2261509","DOI":"10.1080\/19420862.2023.2261509","volume":"15","author":"HP Grimm","year":"2023","unstructured":"Grimm HP, Schumacher V, Sch\u00e4fer M, Imhof-Jung S, Freskg\u00e5rd PO, Brady K, et al. Delivery of the Brainshuttle\u2122 amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans. mAbs. 2023;15(1):2261509.","journal-title":"mAbs"},{"issue":"9","key":"836_CR57","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","volume":"64","author":"S Gilman","year":"2005","unstructured":"Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64(9):1553\u201362.","journal-title":"Neurology"},{"issue":"1","key":"836_CR58","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ymthe.2016.10.002","volume":"25","author":"I Petrushina","year":"2017","unstructured":"Petrushina I, Davtyan H, Hovakimyan A, Davtyan A, Passos GF, Cribbs DH, et al. Comparison of efficacy of preventive and therapeutic vaccines targeting the N terminus of \u03b2-Amyloid in an animal model of Alzheimer\u2019s disease. Mol Ther J Am Soc Gene Ther. 2017;25(1):153\u201364.","journal-title":"Mol Ther J Am Soc Gene Ther"},{"issue":"1","key":"836_CR59","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.expneurol.2012.07.022","volume":"238","author":"F Bard","year":"2012","unstructured":"Bard F, Fox M, Friedrich S, Seubert P, Schenk D, Kinney GG, et al. Sustained levels of antibodies against A\u03b2 in amyloid-rich regions of the CNS following intravenous dosing in human APP Transgenic mice. Exp Neurol. 2012;238(1):38\u201343.","journal-title":"Exp Neurol"},{"issue":"1","key":"836_CR60","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1172\/JCI25410","volume":"116","author":"Y Levites","year":"2006","unstructured":"Levites Y, Das P, Price RW, Rochette MJ, Kostura LA, McGowan EM, et al. Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an alzheimer disease mouse model. J Clin Invest. 2006;116(1):193\u2013201.","journal-title":"J Clin Invest"},{"issue":"5","key":"836_CR61","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00401-015-1484-2","volume":"130","author":"JP Fuller","year":"2015","unstructured":"Fuller JP, Stavenhagen JB, Christensen S, Kartberg F, Glennie MJ, Teeling JL. Comparing the efficacy and neuroinflammatory potential of three anti-abeta antibodies. Acta Neuropathol (Berl). 2015;130(5):699\u2013711.","journal-title":"Acta Neuropathol (Berl)"},{"issue":"1","key":"836_CR62","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.nbd.2003.09.015","volume":"15","author":"DM Wilcock","year":"2004","unstructured":"Wilcock DM, Munireddy SK, Rosenthal A, Ugen KE, Gordon MN, Morgan D. Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol Dis. 2004;15(1):11\u201320.","journal-title":"Neurobiol Dis"},{"issue":"3","key":"836_CR63","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/85525","volume":"7","author":"BJ Bacskai","year":"2001","unstructured":"Bacskai BJ, Kajdasz ST, Christie RH, Carter C, Games D, Seubert P, et al. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med. 2001;7(3):369\u201372.","journal-title":"Nat Med"},{"issue":"18","key":"836_CR64","doi-asserted-by":"publisher","first-page":"7873","DOI":"10.1523\/JNEUROSCI.22-18-07873.2002","volume":"22","author":"BJ Bacskai","year":"2002","unstructured":"Bacskai BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D, et al. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci Off J Soc Neurosci. 2002;22(18):7873\u20138.","journal-title":"J Neurosci Off J Soc Neurosci"},{"issue":"5","key":"836_CR65","doi-asserted-by":"publisher","first-page":"665","DOI":"10.4161\/mabs.25424","volume":"5","author":"L Gim\u00e9nez-Llort","year":"2013","unstructured":"Gim\u00e9nez-Llort L, Rivera-Hern\u00e1ndez G, Marin-Argany M, S\u00e1nchez-Quesada JL, Villegas S. Early intervention in the 3xTg-AD mice with an amyloid \u03b2-antibody fragment ameliorates first hallmarks of alzheimer disease. mAbs. 2013;5(5):665\u201377.","journal-title":"mAbs"},{"key":"836_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.imlet.2020.07.009","volume":"227","author":"L Fu","year":"2020","unstructured":"Fu L, Zhang Y, Zhang X, Tian W, Zhang W, Jia Y, et al. Preparation and in vitro activity of single chain antibodies against Alzheimer\u2019s disease. Immunol Lett. 2020;227:1\u20137.","journal-title":"Immunol Lett"},{"issue":"3","key":"836_CR67","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S0002-9440(10)63360-3","volume":"165","author":"T Bussi\u00e8re","year":"2004","unstructured":"Bussi\u00e8re T, Bard F, Barbour R, Grajeda H, Guido T, Khan K, et al. Morphological characterization of Thioflavin-S-positive amyloid plaques in Transgenic alzheimer mice and effect of passive Abeta immunotherapy on their clearance. Am J Pathol. 2004;165(3):987\u201395.","journal-title":"Am J Pathol"},{"issue":"2","key":"836_CR68","doi-asserted-by":"publisher","first-page":"e20231363","DOI":"10.1084\/jem.20231363","volume":"221","author":"MP Cadiz","year":"2024","unstructured":"Cadiz MP, Gibson KA, Todd KT, Nascari DG, Massa N, Lilley MT, et al. Aducanumab anti-amyloid immunotherapy induces sustained microglial and immune alterations. J Exp Med. 2024;221(2):e20231363.","journal-title":"J Exp Med"},{"key":"836_CR69","doi-asserted-by":"publisher","first-page":"105365","DOI":"10.1016\/j.nbd.2021.105365","volume":"154","author":"J Janssens","year":"2021","unstructured":"Janssens J, Hermans B, Vandermeeren M, Barale-Thomas E, Borgers M, Willems R, et al. Passive immunotherapy with a novel antibody against 3pE-modified A\u03b2 demonstrates potential for enhanced efficacy and favorable safety in combination with BACE inhibitor treatment in plaque-depositing mice. Neurobiol Dis. 2021;154:105365.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"836_CR70","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13195-021-00809-4","volume":"13","author":"G Leinenga","year":"2021","unstructured":"Leinenga G, Koh WK, G\u00f6tz J. A comparative study of the effects of aducanumab and scanning ultrasound on amyloid plaques and behavior in the APP23 mouse model of alzheimer disease. Alzheimers Res Ther. 2021;13(1):76.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"836_CR71","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s11481-011-9329-9","volume":"7","author":"Q Li","year":"2012","unstructured":"Li Q, Lebson L, Lee DC, Nash K, Grimm J, Rosenthal A, et al. Chronological age impacts immunotherapy and monocyte uptake independent of amyloid load. J Neuroimmune Pharmacol Off J Soc NeuroImmune Pharmacol. 2012;7(1):202\u201314.","journal-title":"J Neuroimmune Pharmacol Off J Soc NeuroImmune Pharmacol"},{"issue":"3","key":"836_CR72","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.nbd.2009.08.007","volume":"36","author":"A Lord","year":"2009","unstructured":"Lord A, Gumucio A, Englund H, Sehlin D, Sundquist VS, S\u00f6derberg L, et al. An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer\u2019s disease. Neurobiol Dis. 2009;36(3):425\u201334.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"836_CR73","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12974-018-1134-4","volume":"15","author":"S S\u00f6llvander","year":"2018","unstructured":"S\u00f6llvander S, Nikitidou E, Gallasch L, Zy\u015bk M, S\u00f6derberg L, Sehlin D, et al. The A\u03b2 protofibril selective antibody mAb158 prevents accumulation of A\u03b2 in astrocytes and rescues neurons from A\u03b2-induced cell death. J Neuroinflammation. 2018;15(1):98.","journal-title":"J Neuroinflammation"},{"issue":"2","key":"836_CR74","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3233\/JAD-140741","volume":"43","author":"S Tucker","year":"2015","unstructured":"Tucker S, M\u00f6ller C, Tegerstedt K, Lord A, Laudon H, Sj\u00f6dahl J, et al. The murine version of BAN2401 (mAb158) selectively reduces amyloid-\u03b2 protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J Alzheimers Dis JAD. 2015;43(2):575\u201388.","journal-title":"J Alzheimers Dis JAD"},{"key":"836_CR75","doi-asserted-by":"publisher","first-page":"103950","DOI":"10.1016\/j.mcn.2024.103950","volume":"130","author":"B Rizoska","year":"2024","unstructured":"Rizoska B, Zachrisson O, Appelkvist P, Bostr\u00f6m E, Bj\u00f6rklund M, Rachalski A, et al. Disease modifying effects of the amyloid-beta protofibril-selective antibody mAb158 in aged Tg2576 Transgenic mice. Mol Cell Neurosci. 2024;130:103950.","journal-title":"Mol Cell Neurosci"},{"issue":"1","key":"836_CR76","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13195-018-0447-y","volume":"10","author":"L Pradier","year":"2018","unstructured":"Pradier L, Blanchard-Br\u00e9geon V, Bohme A, Debeir T, Menager J, Benoit P, et al. SAR228810: an antibody for protofibrillar amyloid \u0392 peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA). Alzheimers Res Ther. 2018;10(1):117.","journal-title":"Alzheimers Res Ther"},{"issue":"20","key":"836_CR77","doi-asserted-by":"publisher","first-page":"5340","DOI":"10.1523\/JNEUROSCI.0695-06.2006","volume":"26","author":"DM Wilcock","year":"2006","unstructured":"Wilcock DM, Alamed J, Gottschall PE, Grimm J, Rosenthal A, Pons J, et al. Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein Transgenic mice. J Neurosci Off J Soc Neurosci. 2006;26(20):5340\u20136.","journal-title":"J Neurosci Off J Soc Neurosci"},{"issue":"1","key":"836_CR78","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/jnr.10721","volume":"74","author":"NB Chauhan","year":"2003","unstructured":"Chauhan NB, Siegel GJ. Intracerebroventricular passive immunization with anti-Abeta antibody in Tg2576. J Neurosci Res. 2003;74(1):142\u20137.","journal-title":"J Neurosci Res"},{"issue":"1","key":"836_CR79","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/nen.0b013e31815f38d2","volume":"67","author":"SMF Tucker","year":"2008","unstructured":"Tucker SMF, Borchelt DR, Troncoso JC. Limited clearance of pre-existing amyloid plaques after intracerebral injection of Abeta antibodies in two mouse models of alzheimer disease. J Neuropathol Exp Neurol. 2008;67(1):30\u201340.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"836_CR80","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1161\/STROKEAHA.121.036873","volume":"53","author":"L Sveikata","year":"2022","unstructured":"Sveikata L, Charidimou A, Viswanathan A. Vessels Sing their arias: the role of vascular amyloid in the age of aducanumab. Stroke. 2022;53(1):298\u2013302.","journal-title":"Stroke"},{"issue":"1","key":"836_CR81","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41582-019-0281-2","volume":"16","author":"SM Greenberg","year":"2020","unstructured":"Greenberg SM, Bacskai BJ, Hernandez-Guillamon M, Pruzin J, Sperling R, van Veluw SJ. Cerebral amyloid angiopathy and alzheimer disease - one peptide, two pathways. Nat Rev Neurol. 2020;16(1):30\u201342.","journal-title":"Nat Rev Neurol"},{"issue":"13","key":"836_CR82","doi-asserted-by":"publisher","first-page":"7013","DOI":"10.1074\/jbc.270.13.7013","volume":"270","author":"SA Gravina","year":"1995","unstructured":"Gravina SA, Ho L, Eckman CB, Long KE, Otvos L, Younkin LH, et al. Amyloid beta protein (A beta) in Alzheimer\u2019s disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J Biol Chem. 1995;270(13):7013\u20136.","journal-title":"J Biol Chem"},{"issue":"4","key":"836_CR83","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/00005072-199804000-00008","volume":"57","author":"NC Alonzo","year":"1998","unstructured":"Alonzo NC, Hyman BT, Rebeck GW, Greenberg SM. Progression of cerebral amyloid angiopathy: accumulation of amyloid-beta40 in affected vessels. J Neuropathol Exp Neurol. 1998;57(4):353\u20139.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"5","key":"836_CR84","doi-asserted-by":"publisher","first-page":"101259","DOI":"10.1016\/j.jbc.2021.101259","volume":"297","author":"BA Irizarry","year":"2021","unstructured":"Irizarry BA, Davis J, Zhu X, Boon BDC, Rozemuller AJM, Van Nostrand WE, et al. Human cerebral vascular amyloid contains both antiparallel and parallel in-register A\u03b240 fibrils. J Biol Chem. 2021;297(5):101259.","journal-title":"J Biol Chem"},{"issue":"1","key":"836_CR85","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1212\/01.wnl.0000223613.57229.24","volume":"67","author":"YW Chen","year":"2006","unstructured":"Chen YW, Gurol ME, Rosand J, Viswanathan A, Rakich SM, Groover TR, et al. Progression of white matter lesions and hemorrhages in cerebral amyloid angiopathy. Neurology. 2006;67(1):83\u20137.","journal-title":"Neurology"},{"issue":"1","key":"836_CR86","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1161\/STROKEAHA.122.040671","volume":"54","author":"A Theodorou","year":"2023","unstructured":"Theodorou A, Palaiodimou L, Malhotra K, Zompola C, Katsanos AH, Shoamanesh A, et al. Clinical, neuroimaging, and genetic markers in cerebral amyloid Angiopathy-Related inflammation: A systematic review and Meta-Analysis. Stroke. 2023;54(1):178\u201388.","journal-title":"Stroke"},{"issue":"10","key":"836_CR87","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1001\/jamaneurol.2020.1782","volume":"77","author":"RW Regenhardt","year":"2020","unstructured":"Regenhardt RW, Thon JM, Das AS, Thon OR, Charidimou A, Viswanathan A, et al. Association between immunosuppressive treatment and outcomes of cerebral amyloid Angiopathy-Related inflammation. JAMA Neurol. 2020;77(10):1261\u20139.","journal-title":"JAMA Neurol"},{"issue":"8","key":"836_CR88","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1523\/JNEUROSCI.5426-06.2007","volume":"27","author":"CM Prada","year":"2007","unstructured":"Prada CM, Garcia-Alloza M, Betensky RA, Zhang-Nunes SX, Greenberg SM, Bacskai BJ, et al. Antibody-mediated clearance of amyloid-beta peptide from cerebral amyloid angiopathy revealed by quantitative in vivo imaging. J Neurosci Off J Soc Neurosci. 2007;27(8):1973\u201380.","journal-title":"J Neurosci Off J Soc Neurosci"},{"issue":"1","key":"836_CR89","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13024-024-00758-0","volume":"19","author":"X Taylor","year":"2024","unstructured":"Taylor X, Noristani HN, Fitzgerald GJ, Oluoch H, Babb N, McGathey T, et al. Amyloid-\u03b2 (A\u03b2) immunotherapy induced microhemorrhages are linked to vascular inflammation and cerebrovascular damage in a mouse model of Alzheimer\u2019s disease. Mol Neurodegener. 2024;19(1):77.","journal-title":"Mol Neurodegener"},{"issue":"27","key":"836_CR90","doi-asserted-by":"publisher","first-page":"6787","DOI":"10.1523\/JNEUROSCI.2377-07.2008","volume":"28","author":"S Schroeter","year":"2008","unstructured":"Schroeter S, Khan K, Barbour R, Doan M, Chen M, Guido T, et al. Immunotherapy reduces vascular amyloid-beta in PDAPP mice. J Neurosci Off J Soc Neurosci. 2008;28(27):6787\u201393.","journal-title":"J Neurosci Off J Soc Neurosci"},{"issue":"5 Suppl","key":"836_CR91","first-page":"S105","volume":"9","author":"W Zago","year":"2013","unstructured":"Zago W, Schroeter S, Guido T, Khan K, Seubert P, Yednock T, et al. Vascular alterations in PDAPP mice after anti-A\u03b2 immunotherapy: implications for amyloid-related imaging abnormalities. Alzheimers Dement J Alzheimers Assoc. 2013;9(5 Suppl):S105\u2013115.","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"issue":"1","key":"836_CR92","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1742-2094-1-24","volume":"1","author":"DM Wilcock","year":"2004","unstructured":"Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, et al. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation. 2004;1(1):24.","journal-title":"J Neuroinflammation"},{"issue":"3","key":"836_CR93","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1523\/JNEUROSCI.4337-04.2005","volume":"25","author":"MM Racke","year":"2005","unstructured":"Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein Transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci Off J Soc Neurosci. 2005;25(3):629\u201336.","journal-title":"J Neurosci Off J Soc Neurosci"},{"issue":"1","key":"836_CR94","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13024-023-00649-w","volume":"18","author":"X Taylor","year":"2023","unstructured":"Taylor X, Clark IM, Fitzgerald GJ, Oluoch H, Hole JT, DeMattos RB, et al. Amyloid-\u03b2 (A\u03b2) immunotherapy induced microhemorrhages are associated with activated perivascular macrophages and peripheral monocyte recruitment in Alzheimer\u2019s disease mice. Mol Neurodegener. 2023;18(1):59.","journal-title":"Mol Neurodegener"},{"issue":"5","key":"836_CR95","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nrn.2018.13","volume":"19","author":"MA Petersen","year":"2018","unstructured":"Petersen MA, Ryu JK, Akassoglou K. Fibrinogen in neurological diseases: mechanisms, imaging and therapeutics. Nat Rev Neurosci. 2018;19(5):283\u2013301.","journal-title":"Nat Rev Neurosci"},{"key":"836_CR96","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/1742-2094-8-115","volume":"8","author":"DM Wilcock","year":"2011","unstructured":"Wilcock DM, Morgan D, Gordon MN, Taylor TL, Ridnour LA, Wink DA, et al. Activation of matrix metalloproteinases following anti-A\u03b2 immunotherapy; implications for microhemorrhage occurrence. J Neuroinflammation. 2011;8:115.","journal-title":"J Neuroinflammation"},{"issue":"2","key":"836_CR97","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3233\/JAD-160023","volume":"54","author":"I Blockx","year":"2016","unstructured":"Blockx I, Einstein S, Guns PJ, Van Audekerke J, Guglielmetti C, Zago W, et al. Monitoring Blood-Brain barrier integrity following Amyloid-\u03b2 immunotherapy using Gadolinium-Enhanced MRI in a PDAPP mouse model. J Alzheimers Dis JAD. 2016;54(2):723\u201335.","journal-title":"J Alzheimers Dis JAD"},{"key":"836_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuropharm.2018.09.001","volume":"143","author":"S Gustafsson","year":"2018","unstructured":"Gustafsson S, Gustavsson T, Roshanbin S, Hultqvist G, Hammarlund-Udenaes M, Sehlin D, et al. Blood-brain barrier integrity in a mouse model of Alzheimer\u2019s disease with or without acute 3D6 immunotherapy. Neuropharmacology. 2018;143:1\u20139.","journal-title":"Neuropharmacology"},{"issue":"1","key":"836_CR99","doi-asserted-by":"publisher","first-page":"15955","DOI":"10.1038\/s41598-021-95535-0","volume":"11","author":"DK Franco-Bocanegra","year":"2021","unstructured":"Franco-Bocanegra DK, Gourari Y, McAuley C, Chatelet DS, Johnston DA, Nicoll JAR, et al. Microglial morphology in Alzheimer\u2019s disease and after A\u03b2 immunotherapy. Sci Rep. 2021;11(1):15955.","journal-title":"Sci Rep"},{"issue":"5","key":"836_CR100","doi-asserted-by":"publisher","first-page":"e1456242024","DOI":"10.1523\/JNEUROSCI.1456-24.2024","volume":"45","author":"KE Foley","year":"2025","unstructured":"Foley KE, Weekman EM, Krick KE, Johnson SN, Sudduth TL, Wilcock DM. Acute communication between microglia and nonparenchymal immune cells in the Anti-A\u03b2 Antibody-Injected cortex. J Neurosci Off J Soc Neurosci. 2025;45(5):e1456242024.","journal-title":"J Neurosci Off J Soc Neurosci"},{"issue":"2","key":"836_CR101","doi-asserted-by":"publisher","first-page":"e25693","DOI":"10.4161\/intv.25693","volume":"2","author":"M Garcia-Alloza","year":"2013","unstructured":"Garcia-Alloza M, Borrelli LA, Thyssen DH, Hickman SE, El Khoury J, Bacskai BJ. Four-dimensional microglia response to anti-A\u03b2 treatment in APP\/PS1xCX3CR1\/GFP mice. Intravital. 2013;2(2):e25693.","journal-title":"Intravital"},{"issue":"1","key":"836_CR102","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.immuni.2023.12.001","volume":"57","author":"A Millet","year":"2024","unstructured":"Millet A, Ledo JH, Tavazoie SF. An exhausted-like microglial population accumulates in aged and APOE4 genotype Alzheimer\u2019s brains. Immunity. 2024;57(1):153\u2013e1706.","journal-title":"Immunity"},{"issue":"5","key":"836_CR103","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1042\/AN20110018","volume":"3","author":"DM Wilcock","year":"2011","unstructured":"Wilcock DM, Zhao Q, Morgan D, Gordon MN, Everhart A, Wilson JG, et al. Diverse inflammatory responses in Transgenic mouse models of Alzheimer\u2019s disease and the effect of immunotherapy on these responses. ASN Neuro. 2011;3(5):249\u201358.","journal-title":"ASN Neuro"},{"issue":"3","key":"836_CR104","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.nbd.2007.07.019","volume":"28","author":"M Garcia-Alloza","year":"2007","unstructured":"Garcia-Alloza M, Ferrara BJ, Dodwell SA, Hickey GA, Hyman BT, Bacskai BJ. A limited role for microglia in antibody mediated plaque clearance in APP mice. Neurobiol Dis. 2007;28(3):286\u201392.","journal-title":"Neurobiol Dis"},{"issue":"12","key":"836_CR105","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1016\/j.febslet.2005.03.070","volume":"579","author":"EB Lee","year":"2005","unstructured":"Lee EB, Leng LZ, Lee VMY, Trojanowski JQ. Meningoencephalitis associated with passive immunization of a Transgenic murine model of Alzheimer\u2019s amyloidosis. FEBS Lett. 2005;579(12):2564\u20138.","journal-title":"FEBS Lett"},{"issue":"7858","key":"836_CR106","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41586-021-03489-0","volume":"593","author":"S Da Mesquita","year":"2021","unstructured":"Da Mesquita S, Papadopoulos Z, Dykstra T, Brase L, Farias FG, Wall M, et al. Meningeal lymphatics affect microglia responses and anti-A\u03b2 immunotherapy. Nature. 2021;593(7858):255\u201360.","journal-title":"Nature"},{"issue":"11","key":"836_CR107","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1093\/brain\/awad188","volume":"146","author":"H Hampel","year":"2023","unstructured":"Hampel H, Elhage A, Cho M, Apostolova LG, Nicoll JAR, Atri A. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain J Neurol. 2023;146(11):4414\u201324.","journal-title":"Brain J Neurol"},{"issue":"2","key":"836_CR108","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3233\/JAD-190874","volume":"73","author":"S Xiao","year":"2020","unstructured":"Xiao S, Song LL, Li JT, Wang H, Yu N, Wang ZQ, et al. Intraperitoneal administration of monoclonal antibody against pathologic A\u03b242 aggregates alleviated cognitive deficits and synaptic lesions in APP\/PS1 mice. J Alzheimers Dis JAD. 2020;73(2):657\u201370.","journal-title":"J Alzheimers Dis JAD"},{"issue":"18","key":"836_CR109","doi-asserted-by":"publisher","first-page":"6630","DOI":"10.3390\/ijms21186630","volume":"21","author":"AR Roda","year":"2020","unstructured":"Roda AR, Montoliu-Gaya L, Serra-Mir G, Villegas S. Both Amyloid-\u03b2 peptide and Tau protein are affected by an Anti-Amyloid-\u03b2 antibody fragment in elderly 3xTg-AD mice. Int J Mol Sci. 2020;21(18):6630.","journal-title":"Int J Mol Sci"},{"key":"836_CR110","doi-asserted-by":"crossref","unstructured":"Welikovitch LA, Mate de Gerando A, Khasnavis A, Bhavsar H, Meltzer JC, Bu\u00e9e L et al. Tau, synapse loss and gliosis progress in an Alzheimer\u2019s mouse model after amyloid-\u03b2 immunotherapy. Brain J Neurol. 2024;awae345.","DOI":"10.1093\/brain\/awae345"},{"issue":"40","key":"836_CR111","doi-asserted-by":"publisher","first-page":"9096","DOI":"10.1523\/JNEUROSCI.1697-05.2005","volume":"25","author":"M Buttini","year":"2005","unstructured":"Buttini M, Masliah E, Barbour R, Grajeda H, Motter R, Johnson-Wood K, et al. Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer\u2019s disease. J Neurosci Off J Soc Neurosci. 2005;25(40):9096\u2013101.","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"836_CR112","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.brainres.2009.05.045","volume":"1280","author":"A Rozkalne","year":"2009","unstructured":"Rozkalne A, Spires-Jones TL, Stern EA, Hyman BT. A single dose of passive immunotherapy has extended benefits on synapses and neurites in an Alzheimer\u2019s disease mouse model. Brain Res. 2009;1280:178\u201385.","journal-title":"Brain Res"},{"issue":"Pt 12","key":"836_CR113","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1093\/brain\/awu280","volume":"137","author":"MM Dorostkar","year":"2014","unstructured":"Dorostkar MM, Burgold S, Filser S, Barghorn S, Schmidt B, Anumala UR, et al. Immunotherapy alleviates amyloid-associated synaptic pathology in an Alzheimer\u2019s disease mouse model. Brain J Neurol. 2014;137(Pt 12):3319\u201326.","journal-title":"Brain J Neurol"},{"issue":"5","key":"836_CR114","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1084\/jem.20171484","volume":"215","author":"ACA Chiang","year":"2018","unstructured":"Chiang ACA, Fowler SW, Savjani RR, Hilsenbeck SG, Wallace CE, Cirrito JR, et al. Combination anti-A\u03b2 treatment maximizes cognitive recovery and rebalances mTOR signaling in APP mice. J Exp Med. 2018;215(5):1349\u201364.","journal-title":"J Exp Med"},{"issue":"50","key":"836_CR115","doi-asserted-by":"publisher","first-page":"12549","DOI":"10.1523\/JNEUROSCI.2080-16.2016","volume":"36","author":"KV Kastanenka","year":"2016","unstructured":"Kastanenka KV, Bussiere T, Shakerdge N, Qian F, Weinreb PH, Rhodes K, et al. Immunotherapy with aducanumab restores calcium homeostasis in Tg2576 mice. J Neurosci Off J Soc Neurosci. 2016;36(50):12549\u201358.","journal-title":"J Neurosci Off J Soc Neurosci"},{"issue":"12","key":"836_CR116","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1038\/nn.4163","volume":"18","author":"MA Busche","year":"2015","unstructured":"Busche MA, Grienberger C, Keskin AD, Song B, Neumann U, Staufenbiel M, et al. Decreased amyloid-\u03b2 and increased neuronal hyperactivity by immunotherapy in Alzheimer\u2019s models. Nat Neurosci. 2015;18(12):1725\u20137.","journal-title":"Nat Neurosci"},{"issue":"45","key":"836_CR117","doi-asserted-by":"publisher","first-page":"14108","DOI":"10.1523\/JNEUROSCI.2055-09.2009","volume":"29","author":"B Biscaro","year":"2009","unstructured":"Biscaro B, Lindvall O, Hock C, Ekdahl CT, Nitsch RM. Abeta immunotherapy protects morphology and survival of adult-born neurons in doubly Transgenic APP\/PS1 mice. J Neurosci Off J Soc Neurosci. 2009;29(45):14108\u201319.","journal-title":"J Neurosci Off J Soc Neurosci"},{"issue":"2","key":"836_CR118","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3233\/JAD-2010-101602","volume":"23","author":"Y Liu","year":"2011","unstructured":"Liu Y, Lee MK, James MM, Price DL, Borchelt DR, Troncoso JC, et al. Passive (amyloid-\u03b2) immunotherapy attenuates monoaminergic axonal degeneration in the A\u03b2PPswe\/PS1dE9 mice. J Alzheimers Dis JAD. 2011;23(2):271\u20139.","journal-title":"J Alzheimers Dis JAD"},{"issue":"5","key":"836_CR119","doi-asserted-by":"publisher","first-page":"e4263","DOI":"10.1002\/nbm.4263","volume":"33","author":"J G\u00fcell-Bosch","year":"2020","unstructured":"G\u00fcell-Bosch J, Lope-Piedrafita S, Esquerda-Canals G, Montoliu-Gaya L, Villegas S. Progression of Alzheimer\u2019s disease and effect of scFv-h3D6 immunotherapy in the 3xTg-AD mouse model: an in vivo longitudinal study using magnetic resonance imaging and spectroscopy. NMR Biomed. 2020;33(5):e4263.","journal-title":"NMR Biomed"},{"issue":"26","key":"836_CR120","doi-asserted-by":"publisher","first-page":"6213","DOI":"10.1523\/JNEUROSCI.0664-05.2005","volume":"25","author":"RE Hartman","year":"2005","unstructured":"Hartman RE, Izumi Y, Bales KR, Paul SM, Wozniak DF, Holtzman DM. Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer\u2019s disease. J Neurosci Off J Soc Neurosci. 2005;25(26):6213\u201320.","journal-title":"J Neurosci Off J Soc Neurosci"},{"issue":"15","key":"836_CR121","doi-asserted-by":"publisher","first-page":"6331","DOI":"10.1523\/JNEUROSCI.22-15-06331.2002","volume":"22","author":"LA Kotilinek","year":"2002","unstructured":"Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, Hyman BT, et al. Reversible memory loss in a mouse Transgenic model of Alzheimer\u2019s disease. J Neurosci Off J Soc Neurosci. 2002;22(15):6331\u20135.","journal-title":"J Neurosci Off J Soc Neurosci"},{"issue":"10","key":"836_CR122","doi-asserted-by":"publisher","first-page":"944","DOI":"10.3390\/pharmaceutics12100944","volume":"12","author":"AR Roda","year":"2020","unstructured":"Roda AR, Esquerda-Canals G, Mart\u00ed-Cl\u00faa J, Villegas S. Cognitive impairment in the 3xTg-AD mouse model of Alzheimer\u2019s disease is affected by A\u03b2-ImmunoTherapy and cognitive stimulation. Pharmaceutics. 2020;12(10):944.","journal-title":"Pharmaceutics"},{"issue":"7","key":"836_CR123","doi-asserted-by":"publisher","first-page":"4292","DOI":"10.1074\/jbc.M511018200","volume":"281","author":"EB Lee","year":"2006","unstructured":"Lee EB, Leng LZ, Zhang B, Kwong L, Trojanowski JQ, Abel T, et al. Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) Transgenic mice. J Biol Chem. 2006;281(7):4292\u20139.","journal-title":"J Biol Chem"},{"issue":"2","key":"836_CR124","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3233\/JAD-132789","volume":"41","author":"NF Fitz","year":"2014","unstructured":"Fitz NF, Castranio EL, Carter AY, Kodali R, Lefterov I, Koldamova R. Improvement of memory deficits and amyloid-\u03b2 clearance in aged APP23 mice treated with a combination of anti-amyloid-\u03b2 antibody and LXR agonist. J Alzheimers Dis JAD. 2014;41(2):535\u201349.","journal-title":"J Alzheimers Dis JAD"},{"issue":"1","key":"836_CR125","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13195-018-0384-9","volume":"10","author":"K Herline","year":"2018","unstructured":"Herline K, Prelli F, Mehta P, MacMurray C, Go\u00f1i F, Wisniewski T. Immunotherapy to improve cognition and reduce pathological species in an Alzheimer\u2019s disease mouse model. Alzheimers Res Ther. 2018;10(1):54.","journal-title":"Alzheimers Res Ther"},{"issue":"36","key":"836_CR126","doi-asserted-by":"publisher","first-page":"33012","DOI":"10.1074\/jbc.M203193200","volume":"277","author":"MH Mohajeri","year":"2002","unstructured":"Mohajeri MH, Saini K, Schultz JG, Wollmer MA, Hock C, Nitsch RM. Passive immunization against beta-amyloid peptide protects central nervous system (CNS) neurons from increased vulnerability associated with an Alzheimer\u2019s disease-causing mutation. J Biol Chem. 2002;277(36):33012\u20137.","journal-title":"J Biol Chem"},{"issue":"2","key":"836_CR127","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.nbd.2008.10.011","volume":"33","author":"TL Spires-Jones","year":"2009","unstructured":"Spires-Jones TL, Mielke ML, Rozkalne A, Meyer-Luehmann M, de Calignon A, Bacskai BJ, et al. Passive immunotherapy rapidly increases structural plasticity in a mouse model of alzheimer disease. Neurobiol Dis. 2009;33(2):213\u201320.","journal-title":"Neurobiol Dis"},{"issue":"34","key":"836_CR128","doi-asserted-by":"publisher","first-page":"10879","DOI":"10.1523\/JNEUROSCI.23-34-10879.2003","volume":"23","author":"JA Lombardo","year":"2003","unstructured":"Lombardo JA, Stern EA, McLellan ME, Kajdasz ST, Hickey GA, Bacskai BJ, et al. Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J Neurosci Off J Soc Neurosci. 2003;23(34):10879\u201383.","journal-title":"J Neurosci Off J Soc Neurosci"},{"issue":"2","key":"836_CR129","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.neuron.2020.10.008","volume":"109","author":"Y Chen","year":"2021","unstructured":"Chen Y, Strickland MR, Soranno A, Holtzman DM, Apolipoprotein E. Structural insights and links to alzheimer disease pathogenesis. Neuron. 2021;109(2):205\u201321.","journal-title":"Neuron"},{"issue":"1","key":"836_CR130","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41467-019-14279-8","volume":"11","author":"EM Reiman","year":"2020","unstructured":"Reiman EM, Arboleda-Velasquez JF, Quiroz YT, Huentelman MJ, Beach TG, Caselli RJ, et al. Exceptionally low likelihood of Alzheimer\u2019s dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nat Commun. 2020;11(1):667.","journal-title":"Nat Commun"},{"issue":"4","key":"836_CR131","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/0896-6273(93)90070-8","volume":"11","author":"GW Rebeck","year":"1993","unstructured":"Rebeck GW, Reiter JS, Strickland DK, Hyman BT. Apolipoprotein E in sporadic Alzheimer\u2019s disease: allelic variation and receptor interactions. Neuron. 1993;11(4):575\u201380.","journal-title":"Neuron"},{"issue":"20","key":"836_CR132","doi-asserted-by":"publisher","first-page":"9649","DOI":"10.1073\/pnas.90.20.9649","volume":"90","author":"DE Schmechel","year":"1993","unstructured":"Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of Apolipoprotein E genotype in late-onset alzheimer disease. Proc Natl Acad Sci U S A. 1993;90(20):9649\u201353.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"836_CR133","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/ana.410380219","volume":"38","author":"SM Greenberg","year":"1995","unstructured":"Greenberg SM, Rebeck GW, Vonsattel JP, Gomez-Isla T, Hyman BT. Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol. 1995;38(2):254\u20139.","journal-title":"Ann Neurol"},{"issue":"3","key":"836_CR134","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/0306-4522(95)00331-C","volume":"69","author":"Z Nagy","year":"1995","unstructured":"Nagy Z, Esiri MM, Jobst KA, Johnston C, Litchfield S, Sim E, et al. Influence of the Apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer\u2019s disease. Neuroscience. 1995;69(3):757\u201361.","journal-title":"Neuroscience"},{"issue":"4","key":"836_CR135","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1212\/WNL.50.4.961","volume":"50","author":"SM Greenberg","year":"1998","unstructured":"Greenberg SM, Vonsattel JP, Segal AZ, Chiu RI, Clatworthy AE, Liao A, et al. Association of Apolipoprotein E epsilon2 and vasculopathy in cerebral amyloid angiopathy. Neurology. 1998;50(4):961\u20135.","journal-title":"Neurology"},{"issue":"7","key":"836_CR136","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1097\/NEN.0b013e31829a25b9","volume":"72","author":"PT Nelson","year":"2013","unstructured":"Nelson PT, Pious NM, Jicha GA, Wilcock DM, Fardo DW, Estus S, et al. APOE-\u03b52 and APOE-\u03b54 correlate with increased amyloid accumulation in cerebral vasculature. J Neuropathol Exp Neurol. 2013;72(7):708\u201315.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"3","key":"836_CR137","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings J, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2023;10(3):362\u201377.","journal-title":"J Prev Alzheimers Dis"},{"key":"836_CR138","doi-asserted-by":"publisher","first-page":"1412006","DOI":"10.3389\/fnagi.2024.1412006","volume":"16","author":"KE Foley","year":"2024","unstructured":"Foley KE, Wilcock DM. Three major effects of APOE\u03b54 on A\u03b2 immunotherapy induced ARIA. Front Aging Neurosci. 2024;16:1412006.","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"836_CR139","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13024-017-0156-1","volume":"12","author":"JE Pankiewicz","year":"2017","unstructured":"Pankiewicz JE, Baquero-Buitrago J, Sanchez S, Lopez-Contreras J, Kim J, Sullivan PM, et al. APOE genotype differentially modulates effects of Anti-A\u03b2, passive immunization in APP Transgenic mice. Mol Neurodegener. 2017;12(1):12.","journal-title":"Mol Neurodegener"},{"issue":"1","key":"836_CR140","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1073\/pnas.93.1.452","volume":"93","author":"B Solomon","year":"1996","unstructured":"Solomon B, Koppel R, Hanan E, Katzav T. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the alzheimer beta-amyloid peptide. Proc Natl Acad Sci U S A. 1996;93(1):452\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"836_CR141","unstructured":"Modified titration of donanemab demonstrated reduction of ARIA-E in early symptomatic Alzheimer\u2019s disease patients in phase 3b study. [Internet]. Eli. 2024 Oct. Available from: https:\/\/www.prnewswire.com\/news-releases\/modified-titration-of-donanemab-demonstrated-reduction-of-aria-e-in-early-symptomatic-alzheimers-disease-patients-in-phase-3b-study-302290351.html"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00836-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-025-00836-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00836-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T16:04:41Z","timestamp":1747152281000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-025-00836-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":141,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["836"],"URL":"https:\/\/doi.org\/10.1186\/s13024-025-00836-x","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,13]]},"assertion":[{"value":"25 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"57"}}